| PTC Therapeutics
PIVOT-HD Phase 2 Readout
Forward Looking Statements
2
This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in
this presentation, other than statements of historic fact, are forward-looking statements, including statements with respect to the future expectations, plans
and prospects for PTC, PTC's strategy, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions
and responses and other matters, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other
forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target,"
"potential," "will," "would," "could," "should," "continue," and similar expressions.
PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result
of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for
PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC's license and
collaboration agreement with Novartis Pharmaceuticals Corporation including its right to receive development, regulatory and sales milestones, profit sharing
and royalty payments from Novartis; significant business effects, including the effects of industry, market, economic, political or regulatory conditions;
changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates;
PTC's scientific approach and general development progress; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future
for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most
recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to
carefully consider all such factors.
As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products.
There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful.
The forward-looking statements contained herein represent PTC's views only as of the date of this presentation and PTC does not undertake or plan to
update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other
circumstances occurring after the date of this presentation except as required by law. |
